Screener
Gyre Therapeutics, Inc. GYRE Gyre Pharmaceuticals — Selling General And Administrative Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
| Line item | Gyre Pharmaceuticals | Gyre | Total |
|---|---|---|---|
| Selling and marketing | 13,754 | — | 13,754 |
| Research and development | 9,697 | 4,603 | 14,300 |
| Research and development - related parties | 4,836 | — | 4,836 |
| General and administrative | 4,268 | 3,594 | 7,862 |
| Transaction costs | — | 502 | 502 |
| Total segment operating expenses | 34,764 | 8,699 | 43,463 |
| Loss from segment operations | (5,667) | (8,691) | (14,358) |
| Other segment (loss) income, net: |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s gyre pharmaceuticals — selling general and administrative expense?
- Gyre Therapeutics, Inc. (GYRE) reported gyre pharmaceuticals — selling general and administrative expense of $4.27M in Q2 2026.
- What does gyre pharmaceuticals — selling general and administrative expense mean?
- This metric captures the overhead costs associated with the pharmaceutical segment, including marketing, legal, administrative salaries, and general corporate support. It measures the operational efficiency of the business unit in managing its non-research functions. Monitoring this helps investors understand the scalability of the segment's commercial operations.
Ask your AI about Gyre Therapeutics, Inc.'s gyre pharmaceuticals — selling general and administrative expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude